European NGS Services Market - Industry Analysis, Market Size, Share, Trends, Growth and Forecast 2021 - 2026
European NGS Services Market Overview
The European NGS Services market size is estimated to reach $1.86 billion by 2026, growing at a CAGR of 15.9% during the forecast period 2021-2026. Next-generation sequencing (NGS) is a massively parallel sequencing technology that helps to provide extremely high throughput, scalability, and speed. NGS is used to identify the order of nucleotides in entire genomes or certain specific regions of the DNA or RNA. This technology has allowed labs to conduct various studies regarding biological systems that were previously impossible. Some of the major technologies used by the European NGS Services include Nanopore sequencing, Ion Semiconductor sequencing, and Pyro-sequencing. The services provided through NGS sequencing include Drug Discovery, Exome Sequencing, Gene Panels, and Whole Genome Sequencing. The increase in the prevalence of cancer is driving the market during the forecast period. However, high costs act as a key challenge for the European NGS Services Industry.
The report: “European NGS Services Market Forecast
(2021-2026)”, by Industry ARC, covers an in-depth analysis of the following
segments of the European NGS
By Technology: Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing (IOS), Sequencing by Ligation (SBL), Pyro-sequencing, Single-Molecule Real-Time (SMRT), and Nanopore Sequencing.
By Type: Products, Consumables, and Services.
By Application: Diagnostics, Reproductive Health, Clinical Investigation, Drug Discovery, Research, and Others.
By Disease: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Inherited Rare Diseases, Prenatal and Neonatal Disorders, and Other Diseases
By End User: Academic & Research Institutes, Pharmaceutical & Biotechnological Companies, Diagnostic Centers & Healthcare Facilities, Contract Research Organizations, and Others.
By Country: Germany, UK, France, Italy, Spain, Russia, and the Rest of Europe.
- Geographically, the UK segment of the European NGS Services Market accounted for the largest share in 2020 owing to the increase in healthcare expenditure.
- The rise in the awareness regarding NGS for the diagnosis of cancers and rare diseases is driving the European NGS Services Market during the forecast period. However, the time necessary for the development of NGS services acts as a challenge for demand generation.
- Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the European NGS Services Market Report.
European NGS Services Market Share, By Country, 2020(%)
For More Details on This Report - Request for Sample
European NGS Services Market Segment Analysis-By Technology
Based on Technology, the European NGS Services Market can be segmented into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing (IOS), Sequencing by Ligation (SBL), Pyro-sequencing, Single-Molecule Real-Time (SMRT), and Nanopore Sequencing. The Ion Semiconductor Sequencing segment is anticipated to have the largest share of the market in 2020 and is poised to dominate the market during the forecast period 2021-2026. IOS is a DNA sequencing method based on the detection of Hydrogen ions emitted during the DNA polymerization process. They are used extensively in genomic sequencing, drug resistance testing, microbial characterization, and targeted sequencing in cancer studies. The Nanopore sequencing segment is projected to grow at a CAGR of 16.4% during the forecast period. They are one of the most recent additions to the next-generation sequencing technologies and are used to determine the sequence of DNA/RNA bases.
European NGS Services Market Segment Analysis-By Disease
The European NGS Services Market based on Disease can be further segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Inherited Rare Diseases, Prenatal and Neonatal Disorders, and Other Diseases. The Breast Cancer segment accounted for the largest share of the market in 2020. Breast cancer occurs when the breast cells divide and grow uncontrollably. The accumulation of these cells leads to a lump or mass which can metastasize to the lymph nodes or other parts of the body. Breast cancer is the most common type of cancer in Europe with around 576,300 cases in 2020. The Prenatal and Neonatal Disorders segment is also anticipated to witness the fastest growth during the forecast period at a CAGR of 16.7% owing to the rising awareness regarding early detection of various monogenic disorders.
European NGS Services Market Segment Analysis-By Country
The European NGS Services Market based on Country can be segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. The UK segment is projected to dominate the European NGS Services market during the forecast period 2021-2026 with a market share of 24% owing to the presence of highly developed healthcare infrastructure, favorable government reimbursement policies, high patient awareness levels, and rising healthcare expenditure in the country. Moreover, the presence of various small and medium-scale NGS service providers in the country ensures lower costs, higher innovation, and more options for the end-user industries. Germany is also anticipated to grow at a rapid pace during the forecast period owing to the surge in the prevalence of cancers in the country. NGS services enable medical professionals to gain a large amount of genomic information about cancers.
European NGS Services Market DriversIncrease Cancer Prevalence is Projected to Drive Market Growth
The rise in the prevalence of cancer is driving the market for NGS Services in Europe to enhance diagnostic capabilities. Even though Europe represents only 9.7% of the world population, the region accounted for 22.8% of the total cancer cases and 19.6% of the cancer deaths worldwide. The risk of an individual developing cancer during their lifetime in Western Europe was 34.90% for males and 27.85% for females. Meanwhile, the risk of cancer death was 13% for males and 8.84% for females. This is much higher than the global average cancer incidence rates, which were 22.60% for males and 18.55% for females in 2020.
The rise in Awareness of Prenatal Disorders is Anticipated to Boost Service Demand
High awareness regarding prenatal disorders is driving the market for NGS services as they enable early detection of conditions such as Downs syndrome, Edwards syndrome, Palau Syndrome and Turner Syndrome. According to a study by the Massachusetts General Hospital (MGH) and international Down syndrome organizations, the number of babies being born per year with Down syndrome in Europe decreased by an average of 54% owing to the rise in awareness of prenatal screening. Furthermore, of the 5.2 million births in the European Union (EU) each year, around 104,000 or 2.5% will be born with various congenital anomalies.
European NGS Services Market Challenges
The High Initial
Investment Costs is Anticipated to Hamper Market Growth
The high initial investment costs necessary for procuring the expensive equipment, software, and consumables essential for NGS services are challenging growth opportunities. The large capital required for these systems acts as an entry barrier for small and medium-scale laboratories in the region by preventing them access to the new technology. This forces them to continue using less effective traditional techniques for various applications. An advanced DNA sequencing machine can sometimes cost around $1 million. For instance, Illumina’s low end sequencing machine NovaSeq 5000 costs around $850,000 while the NovaSeq 6000 can cost $985,000.
Covid-19 Pandemic and Subsequent Restrictions is Projected to Limit Growth Opportunities
The Covid-19 Pandemic had a devastating impact on the European healthcare sector. For instance, the UK registered more than 8.81 million Covid-19 cases and 140,000 deaths while Russia recorded 8.15 million cases and 228,000 deaths. With the emergence of new variants that are more resistant to vaccines, the pandemic is anticipated to last longer than expected. This is challenging the demand for NGS services in Europe as the healthcare system is diverting its limited funds to combat the spread of the pandemic by expanding hospital capacity, increasing vaccine production and distribution, preventing staff shortage, and procuring essential drugs and medical equipment. The Covid-19 pandemic has increased the cost of running frontline National Health Service (NHS) services by around £4 to £5 billion a year in the UK.
European NGS Services Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and expansions are key strategies adopted by players in the European NGS Services Market. The top 10 companies of the industry include:
- Genomnia SRL
- Mina INC
- Macrogen Inc
- Microsynth AG
- Source BioScience
- DNA Vision SA
- Eurofins Genomics Inc
- Beijing Genomics Institute (BGI)
- Comprehensive Biomarker Center GMBH (CBC)
- In October 2021, Roche announced the launch of the AVENIO Tumor Tissue CGP Kit. The new kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house.
- In August 2019, Eurofins Genomics announced that they have completed the acquisition of Blue Heron Biotech, a company specializing in advanced gene synthesis. Blue Heron is renowned for its expertise in gene synthesis and subcloning, which allows them to successfully construct sizable gene constructs that other companies find difficult to produce.
Real-Time Polymerase Chain Reaction Systems Market - Forecast (2021 - 2026)
Report Code: CMR 1039
Expression Market - Forecast (2021 - 2026)
Report Code: HCR 36422
For more Lifesciences and Healthcare Market reports, please click here